NCT06784830 Nursing Interventions for Alzheimer's Patients During PET/CT Imaging
| NCT ID | NCT06784830 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sichuan Provincial People's Hospital |
| Condition | Alzheimer's Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-06-15 |
| Primary Completion | 2025-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-06-15 with a primary completion date of 2025-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The impact of nursing Interventions during PET/CT imaging in Alzheimer's patients on image quality and patient satisfaction will be assessed in 200 patients.
Eligibility Criteria
Inclusion Criteria: * Meet the criteria for diagnosing dementia as described in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-R), Use the diagnostic criteria for AD from the National Institute of Neurology, Speech and Communication Disorders and Stroke - Alzheimer's Disease and Related Disorders (NINCDS-ADRDA) or the National Institute on Aging and Alzheimer's Disease Association (NIA-AA). Exclusion Criteria: * Patients with a history of stroke and focal neurological signs, and imaging findings consistent with small cerebral vascular disease (Fazekas score ≥2); * The presence of other neurological disorders that can cause brain dysfunction (e.g., depression, brain tumors, Parkinson's disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, Normal facial pressure hydrocephalus); * The presence of other systemic diseases that can cause cognitive impairment (such as liver insufficiency, renal insufficiency, thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.); * There is mental and neurological retardation. * There are other diseases that are known to cause cognitive impairment.
Contact & Investigator
Hao Wang, Doctor
STUDY DIRECTOR
Sichuan Provincial People's Hospital
Frequently Asked Questions
Who can join the NCT06784830 clinical trial?
This trial is open to participants of all sexes, studying Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06784830 currently recruiting?
Yes, NCT06784830 is actively recruiting participants. Contact the research team at 474556259@qq.com for enrollment information.
Where is the NCT06784830 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT06784830 clinical trial?
NCT06784830 is sponsored by Sichuan Provincial People's Hospital. The principal investigator is Hao Wang, Doctor at Sichuan Provincial People's Hospital. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.